Ceryvyn Reports AUD 30 Million Cash and Progress in CYV-101 Preclinical Studies

Reinstatement and Rebranding Marks New Chapter

After a trading suspension, Ceryvyn Therapeutics Limited resumed ASX trading on 3 June 2026, now under the ticker CYV following shareholder approval of its name change in early July. This rebranding signals a strategic pivot towards developing therapies for lymphangioleiomyomatosis (LAM), a rare and debilitating pulmonary disease with few treatment options.

Progressing CYV-101 Through Preclinical Milestones

The company’s lead candidate, CYV-101, a fusion protein targeting VEGF-C and VEGF-D pathways implicated in LAM, is currently in Stage 1 preclinical development. This phase focuses on nebulisation feasibility; testing inhalation delivery to directly address lung pathology. Preclinical biology and inhalation studies are ongoing, with animal safety and tolerability assessments shaping the path forward. Advancement to subsequent stages hinges on data meeting predefined scientific and operational benchmarks reviewed by the board.

Scientific Advisory Board Brings Rare Disease Expertise

To bolster development, Ceryvyn has established a Scientific Advisory Board composed of internationally recognised LAM and pulmonary medicine experts, including Professors Deborah Yates and Frank McCormack, and Dr Elizabeth Daugherity. Their guidance aims to ensure clinical and translational rigor as CYV-101 progresses, reflecting the company’s commitment to grounding its program in robust science.

Intellectual Property Strategy Refocused with New US Patent

In a notable intellectual property move, Ceryvyn withdrew two earlier provisional patents filed in 2025 and replaced them with a new US provisional application centred on nebulised VEGF inhibitors for pulmonary diseases, including LAM. This refocused patent approach may strengthen the company’s proprietary position in an area with significant unmet medical need.

Financial Position Supports Ongoing Development

With AUD 30.0 million in cash at quarter-end and a quarterly operating cash outflow of AUD 1.1 million, Ceryvyn maintains a runway of approximately 27 quarters at current burn rates. Research and development expenses were modest at AUD 0.1 million this quarter, reflecting the early preclinical stage, while administration expenses stood at AUD 1.2 million. Notably, no personnel expenses were recorded, suggesting lean operations or outsourced activities.

Payments to directors totalled AUD 0.3 million, consistent with ASX disclosure rules. The company earned AUD 0.2 million in interest income, partially offsetting operating costs.

Looking Ahead: Data-Driven Progression and Market Updates

Ceryvyn’s development roadmap is clearly staged, with progression contingent on data-driven decisions by the board. The company plans to keep the market informed as key milestones in the LAM program are met. While timelines for Stage 2 and 3 remain undefined, the current focus on nebulisation feasibility and safety is a critical first step in positioning CYV-101 as a differentiated therapeutic candidate.

Investors tracking rare disease biotechs will note Ceryvyn’s methodical approach: rebuilding its platform post-reinstatement, assembling expert guidance, sharpening its IP portfolio, and managing cash prudently. The next quarters should reveal whether CYV-101’s preclinical promise translates into a viable clinical asset in a niche yet underserved market.